THALES
30.6.2022 14:22:10 CEST | Business Wire | Press release
Thales announced today the creation of S3NS, a French company designed to offer public and private organizations in France the power of Google Cloud, fully compliant with France's “Trusted Cloud” label, in partnership with Google Cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005160/en/
The new company, majority owned and controlled by Thales, is under French law and follows the October 2021 partnership announcement between Thales and Google Cloud to jointly develop a locally-compliant Trusted Cloud offering. Thales and Google Cloud are committed to helping companies and public institutions to innovate and accelerate their digital transformation in ways that afford autonomy, compliant sovereignty, and the greatest possible benefits for their customers and users.
Meeting the French “Trusted Cloud”
S3NS will offer from the second half of 2024 its “trusted cloud” offering that will ultimately combine full performance, services and applications of Google Cloud technology while allowing protection against extraterritorial foreign laws and in compliance with the requirements of the “Trusted Cloud” label of France’s Information Systems Security Agency (ANSSI) in the frame of the French State strategy. S3NS will directly operate three data centers to ensure data and workload localisation in France. Both data center availability and engineering assistance will be available this year already and the recruitment of engineers who will operate the “Trusted Cloud” will begin.
A first milestone with an offering already available
S3NS' first offering is "Local control with S3NS", which will offer Google Cloud customers in France continued high public cloud performance, with added capabilities to localize clients’ data in France or in Europe, as needed or preferred. Customers will be able to restrict data access for administrative service and technical support solely to European Union locations. Cryptographic control of data access can be achieved with external encryption key management from S3NS. This first offering brings compliance with additional automation to simplify operations, along with additional auditability and transparency to increase customer confidence in cloud operations.
Committing partners already
To best support customers in this transition to the “Trusted Cloud”, S3NS is finalizing specific partnership agreements with various players in France's growing digital ecosystem. Partners will be able to support S3NS customers in their cloud and digital sovereignty strategy, as they migrate and operate their workloads and applications securely, with the help of S3NS’ and other managed services.
“The S3NS offering is the best of both worlds: the agility and wide range of services of a cloud hyperscaler combined with the security and data protection of a cybersecurity leader. This step marks the beginning of a technological and industrial adventure which will engage all the French economic players attached to a trusted solution. As a leader in critical information systems, Thales is once again demonstrating its ability to be a driving force in disruptive technologies.” Marc Darmon, Executive Vice President, Secure Communications and Information Systems at Thales.
“The creation of S3NS, progress on the definition of our Trusted Cloud offering and the availability of our 'Local controls with S3NS' is the result of many months of collaboration between Thales and the Google Cloud teams. This is a first step and a first milestone this year, before our future solution in compliance with the French 'Trusted Cloud' criteria, which we are working on in parallel. Our objective is to be the first to make such an offering available for certification and based on hyperscale cloud technology. 'Local Controls with S3NS' enables our customers to start their journey to the trusted cloud now.” Cyprien Falque, Managing director of S3NS.
“We are very proud to support our partner Thales and its subsidiary S3NS and its first offering in the French market. This collaboration between our teams reflects on the one hand an understanding of the expectations related to digital sovereignty, and on the other hand a real technological trajectory. We confirm the commitments made together in 2021 and will continue to support digital transformation with offers that combine security and sovereignty, without compromising on performance.” Thomas Kurian, CEO at Google Cloud.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021 the Group generated sales of €16.2 billion.
PLEASE VISIT
https://www.linkedin.com/company/s3nscloud/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005160/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom